MedTrace Logo

Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year

NCT00703768 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2009-02-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate if there is a difference in quality of life (as measured by FACT-P) in patients treated with androgen deprivation therapy (ADT) for biochemical failure (PSA recurrence) following surgery or radiation for prostate cancer depending on when ADT is initiated.

Conditions

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Urology South Shore Research Inc.

    lead OTHER

Principal Investigators

  • Lorne Aaron, MD

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2010-06-30
Completion
2010-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703768 on ClinicalTrials.gov